We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -2.99% | 3.25 | 3.10 | 3.40 | 3.35 | 3.25 | 3.35 | 591,351 | 08:16:32 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.61 | 154.91M |
TIDMAGY
RNS Number : 9494U
Allergy Therapeutics PLC
28 November 2023
TR-1: S tandard form for notification of major holdings
Hot Features
Premium
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible)
1a. Identity of the issuer or the Allergy Therapeutics plc
underlying issuer of existing shares
to which voting rights are attached: Company number: 05141592
Dominion Way, Worthing, West Sussex,
BN14 8SA
----------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify):
----
3. Details of person subject to the notification obligation
Name Abbott Laboratories, an Illinois
corporation
City and country of registered office
(if applicable)
4. Full name of shareholder(s) (if different from 3.)
Name Yissum Holding Limited
----------------------------------------------
City and country of registered office Valletta, Malta
(if applicable)
----------------------------------------------
Name Abbott Laboratories (Chile) Holdco
SpA
----------------------------------------------
City and country of registered office Santiago, Chile
(if applicable)
----------------------------------------------
5. Date on which the threshold was 09/11/2023
crossed or reached:
----------------------------------------------
6. Date on which issuer notified 14/11/2023
(DD/MM/YYYY):
----------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) held in issuer
of 8. A) (total of 8.B (8.A + 8.B)
1 + 8.B 2)
------------------ ---------------------- --------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached Below 3% N/A Below 3% 0
------------------ ---------------------- --------------- --------------------
Position of
previous notification
(if
applicable) 5.06% N/A 5.06% 240,584,571
------------------ ---------------------- --------------- --------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1)
----------------------
N/A 0 0 0% 0%
-------------------- ---------------------- -------------------- ----------------
SUBTOTAL 8.
A
-------------------------------------------- --------------------------------------
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion Period rights that may rights
be acquired if
the instrument
is
exercised/converted.
----------- ------------------------- -------------------------- ----------------
SUBTOTAL 8. B
1
------------------------- -------------------------- ----------------
B 2: Financial Instruments with similar economic effect according to
DTR5.3.1R (1) (b)
Type of financial Expiration Exercise/ Physical Number of % of voting
instrument date Conversion or cash voting rights rights
Period Settlement
---------------- ---------------- ----------------- ----------------
SUBTOTAL
8.B.2
----------------- ----------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled X
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional
rows as necessary)
Name % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-----------------------------------------------
The number and % of voting rights
held
-----------------------------------------------
The date until which the voting rights
will be held
-----------------------------------------------
11. Additional information
Place of completion Chicago, Illinois, United States of America
Date of completion 14/11/2023
--------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUWVSROWUAUAA
(END) Dow Jones Newswires
November 28, 2023 10:03 ET (15:03 GMT)
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
